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Abstract
Background: Racemic isometheptene [(RS)-isometheptene] is an antimigraine drug that due to its cardiovascular
side-effects was separated into its enantiomers, (R)- and (S)-isometheptene. This study set out to characterize the
contribution of each enantiomer to its vasoactive profile. Moreover, rat neurogenic dural vasodilatation was used
to explore their antimigraine mechanism of action.
Methods: Human blood vessel segments (middle meningeal artery, proximal and distal coronary arteries, and saphenous
vein) were mounted in organ baths and concentration response curves to isometheptene were constructed. Calcitonin
gene-related peptide (CGRP)-induced neurogenic dural vasodilation was elicited in the presence of the enantiomers
using a rat closed cranial window model.
Results: The isometheptene enantiomers did not induce any significant contraction in human blood vessels, except in
the middle meningeal artery, when they were administered at the highest concentration (100 μM). Interestingly in rats,
(S)-isometheptene induced more pronounced vasopressor responses than (R)-isometheptene. However, none of these
compounds affected the CGRP-induced vasodilator responses.
Conclusion: The isometheptene enantiomers displayed a relatively safe peripheral vascular profile, as they failed to
constrict the human coronary artery. These compounds do not appear to modulate neurogenic dural CGRP release,
therefore, their antimigraine site of action remains to be determined.
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Background
Migraine is a neurovascular disorder characterized by
recurrent attacks of incapacitating unilateral headaches,
recently interconnected with an overall increased risk of
stroke and cardiovascular disease [1, 2]. Although its exact
pathophysiology has not been elucidated completely,
migraine headache has been associated with activation of
the trigeminovascular system and increased release of calci-
tonin gene-related peptide (CGRP), resulting in dysfunc-
tional nociceptive transmission and neurogenic dural
vasodilatation [3].
The triptans, serotonergic agonists with selective affinity
for 5-HT1B/1D/(1F) receptors, are specific drugs for the
acute treatment. Their mechanism of action has been at-
tributed to a dural perivascular inhibition of CGRP re-
lease, an inhibition of central nociception and/or a
postjunctional constriction of (cranial) blood vessels [4–
6]. Because of the latter, the triptans are contraindicated
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in patients with cardiovascular risk factors or a history of
cardiovascular disease.
Isometheptene is a sympathomimetic racemic drug
available by prescription or over the counter in several
countries, that has long been used for the acute treatment
of primary headaches [7, 8]. Nevertheless, a few case re-
ports of acute intracranial vasoconstriction after its use [9,
10] highlight its presumed vasoactive properties [11].
Given that the development of new antimigraine agents
with a beneficial cardiovascular safety profile is crucial,
Tonix Pharmaceuticals™ separated isometheptene racem-
ate into its enantiomers, (S)-isometheptene and (R)-iso-
metheptene, a mixed-acting (tyramine-like/minor direct
α1-adrenoceptor) and an indirect-acting (tyramine-like)
adrenergic receptor agonist, respectively. Additionally,
(R)-isometheptene is an imidazoline I1 receptor agonist
[12], and previous studies have shown that: (i) imidazoline
I1 receptor knockout mice have a potentiated nociceptive
perception, suggesting that this receptor could be associ-
ated with an endogenous analgesia system [13]; (ii)
(R)-isometheptene decreased trigeminal sensitivity in two
rat models of chronic migraine [14]; and (iii) imidazoline
I1 receptor agonists, like moxonidine and agmatine in-
duced a prejunctional inhibition of the vasodepressor sen-
sory CGRPergic outflow in pithed rats [15]. Together,
these findings suggest that a potential antimigraine action
of (R)-isometheptene could be mediated by inhibition of
the trigeminal system. Hence, we hypothesized that the
use of only (R)-isometheptene will maintain its antimi-
graine therapeutic effect, while the major side effects asso-
ciated with the racemate or (S)-isometheptene (i.e. cranial
vasoconstriction) will be diminished [16].
On this basis, the present study set out to analyse the
effects of the isometheptene enantiomers and the racem-
ate on human isolated blood vessels (i.e. middle menin-
geal artery, proximal and distal coronary arteries, as well
as saphenous vein) and trigeminal CGRP-induced neuro-
genic dural vasodilation in anaesthetized rats (through a
closed cranial window).
Materials and methods
Human isolated blood vessels
Middle meningeal arteries [internal diameter (ID) 0.5–1.5
mm] were obtained from 11 patients (3 males, 8 females;
mean age 53 ± 5 years) who underwent neurosurgical in-
terventions requiring a trepanation of the skull. During
surgery, the dura mater together with a small piece of
meningeal artery was collected in a sterile organ protect-
ing solution and was immediately transported to the
laboratory. The meningeal arteries were dissected and
placed in a cold (4 °C) oxygenated Krebs bicarbonate solu-
tion with the following composition (mmol/L): NaCl 119,
KCl 4.7, CaCl2 1.25, MgSO4 1.2, KH2PO4 1.2, NaHCO2 25
and glucose 11.1; pH 7.4.
Saphenous veins (ID 0.5–3mm) were obtained from 11
patients (10 males, 1 female; mean age 71 ± 2 years) who
underwent coronary artery bypass surgery. Immediately
after surgery, veins were placed in cold (4 °C) oxygenated
Krebs buffer solution with the following composition
(mmol/L): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2,
KH2PO4 1.2, NaHCO2 25 and glucose 8.3; pH 7.4.
Proximal (ID 2–3mm) and distal (ID 0.5–1.0 mm) cor-
onary arteries were obtained from 10 heart valve donors
(6 males, 4 females; mean age 40 ± 5 years) who died of
non-cardiac disorders: four traumatic brain injury, one
benzodiazepine overdose, three anoxic encephalopathy
and two cerebrovascular accident. The hearts were pro-
vided by the Heart Valve Bank Beverwijk (at that time still
located in Rotterdam) from Dutch post-mortem donors,
after donor mediation by The Dutch Transplantation
Foundation (Leiden, The Netherlands), following removal
of the aortic and pulmonary valves for homograft valve
transplantation. All donors gave permission for research.
Immediately after circulatory arrest, the hearts were stored
at 4 °C in a sterile organ protecting solution and were
brought to the laboratory within the first 24 h of death.
The coronary arteries were dissected and placed in Krebs
buffer with the same composition as the one used for the
saphenous veins (see above). All blood vessels were used
on the same day or stored overnight and used the follow-
ing day for functional experiments.
The middle meningeal arteries and the distal coronary
arteries were cut into ring segments of 1–2 mm length
and suspended in Mulvany myographs on two parallel
steel wires. The tension was normalized to 90% of the
estimated diameter at 100 mmHg [17]. The proximal
coronary arteries and saphenous veins were cut into ring
segments of about 3–4 mm length and suspended on
stainless steel hooks in 15-mL organ baths. The vascular
rings were stretched to a stable pretension of 10–15
mN, the optimal pretension as determined earlier [17],
and changes in tissue force were measured with an iso-
metric force transducer (Harvard, South Natick, MA,
U.S.A.) and recorded on a flatbed recorder (Servogor
124, Goerz, Neudorf, Austria). The buffer was aerated
with 95% O2 and 5% CO2 and was maintained at 37 °C.
The segments were allowed to equilibrate for at least 30
min and were washed every 15 min.
In vitro experimental protocols
Initially, segments were exposed to 30 mM KCl, followed
by 100 mM KCl to determine the reference contractile
response in each segment. Cumulative concentration re-
sponse curves were constructed to (S)-isometheptene,
(R)-isometheptene, isometheptene racemate, sumatrip-
tan and noradrenaline, using whole logarithmic steps (1
nM to 100 μM). Sumatriptan and noradrenaline were
used as positive controls, as previously reported [17].
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Finally, the functional integrity of the endothelium was
assessed by observing the relaxation to substance P (10
nM) in arteries or bradykinin (10 μM) in saphenous
veins after precontraction with the thromboxane A2
analogue U46619 (10–100 nM).
Animals
Twelve male Sprague-Dawley rats (300–350 g; 8–10 weeks
of age), purchased from Harlan Netherlands (Horst, the
Netherlands), were maintained at a 12/12-h light-dark
cycle in a special room at constant temperature (22 ± 2 °C)
and humidity (50%), with food and water ad libitum. Only
male rats were used to avoid crosstalk between CGRP and
hormonal fluctuations of the oestrus cycle previously de-
scribed in this model [18, 19]. Experimental protocols
were approved by the Erasmus Medical Center’s institu-
tional ethics committee (EMC permission protocol num-
ber 3393), in accordance with the European directive
2010/63/EU and the ARRIVE guidelines for reporting
experiments in animals [20].
After anaesthesia with sodium pentobarbital (60 mg/
kg i.p. followed by 18 mg/kg i.v. per hour), the trachea
was cannulated and artificially ventilated (58 strokes/
min.; small animal ventilator SAR 830 series, CWE Inc.,
Ardmore, PA, U.S.A). The adequacy of anaesthesia was
judged by the absence of ocular reflexes and a negative
tail flick test.
End-tidal pCO2 was monitored with a capnograph
(Capstar 100 CWE Inc., PA, U.S.A.) and kept between
35 and 45 mmHg. The left femoral vein and artery were
cannulated for i.v. administration of drugs and monitor-
ing of mean arterial pressure (MAP), respectively. The
animals’ body temperature was maintained at 37 °C by a
homeothermic blanket (Harvard Instruments, Eden-
bridge, Kent, U.K.). The head of each rat was fixed in a
stereotaxic frame and the parietal bone overlying a seg-
ment of the dural middle meningeal artery was drilled
thin, applying cold saline until the artery was clearly vis-
ible. As skull drilling induces vasodilation, animals were
allowed to rest at least for 1 h before the experimental
protocol started. The artery diameter was recorded with
an intravital microscopy setup (MZ16, Leica microsys-
tem Ltd., Heerbrugg, Switzerland) using a cyan blue fil-
ter on a cold light source. A zoom lens (80-450x
magnification) and a camera were used to display images
on a standard PC monitor. The artery diameter (30–
40 μm at baseline) was continuously monitored and
measured with an intravital dimension analyser (IDA
1.2.1.10; U.K.). For periarterial electrical stimulation
(ES), a bipolar stimulating electrode (NE 200X, Clark
Electromedical, Edenbridge, Kent, U.K.) was placed on
the surface of the bone approximately within 200 μm
from the artery. The surface of the closed cranial win-
dow was stimulated at 5 Hz, 1 ms for 10 s (Stimulator
model S88, Grass Instruments, West Warwick, RI,
U.S.A.) with increasing voltage until maximum dilation
was observed.
In vivo experimental protocols
After a stable hemodynamic condition for at least 60min,
baseline values of dural artery diameter and MAP were de-
termined. Subsequently, the 12 rats were randomly divided
into three sets (n = 4 each). In each set, a control vasodila-
tor response of the middle meningeal artery was produced
by either endogenous [released by ES (150–300 μA) or
capsaicin (10 μg/kg, i.v.)] or exogenous CGRP (1 μg/kg,
i.v.). A 30-min interval between control and each subse-
quent vasodilation was allowed for the recovery of baseline
values, and 5min before the next vasodilation, (R)-iso-
metheptene, (S)-isometheptene or the racemate (3mg/kg,
i.v., each) were injected. The administration of the iso-
metheptene enantiomers was alternated, and followed by
racemate. In each case, there was a time interval of 5min
to allow the dural artery diameter and MAP to return to
baseline, before the next vasodilator was administered. We
have previously shown that repeated (up to 5 times) ES
and treatment with capsaicin or CGRP produced reprodu-
cible increases in dural artery diameter (data not shown).
Statistical evaluation
All data are presented as mean ± SEM. The concentra-
tion response curves obtained in the vessels were ana-
lysed using GraphPad software (GraphPad software Inc.,
San Diego, CA, U.S.A.) to calculate the maximal effect
(Emax) and pEC50 values. In case a concentration re-
sponse curve did not reach a plateau, the contraction to
the highest concentration was considered as Emax. Emax
and pEC50 values were compared by unpaired t-test.
The peak increases in dural artery diameter (measured
in arbitrary units) in anaesthetised rats are expressed as
percent change from baseline. Changes in MAP are
expressed in absolute values (mm Hg). A repeated mea-
sures one-way analysis of variance (ANOVA) followed
by Tukey’s test was performed to examine the different
effects per se between isometheptene enantiomers and
the racemate. The dural vasodilator differences between
the variables within one group were compared using an
ANOVA followed by Dunnett’s test. Statistical signifi-
cance was accepted at P < 0.05 (two-tailed).
Compounds
Apart from the anaesthetic (sodium pentobarbital), the
drugs used in the present study were: isometheptene ra-
cemate, (R)-isometheptene and (S)-isometheptene (Tonix
Pharmaceuticals Inc., New York, N.Y., U.S.A.); sumatrip-
tan, bradykinin, noradrenaline, capsaicin, U46619 and
substance P (Sigma Chemical Co., St. Louis, MO, U.S.A);
and rat/human α-CGRP (NeoMPS S.A., Strasbourg,
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France). Capsaicin was dissolved in a mixture of tween 80,
ethanol 70% and water (1:1:8), while the rest of the com-
pounds were dissolved in either distilled water (in vitro) or
physiological saline (in vivo). The doses mentioned in the
text refer to the free base of substances in all cases.
Results
Vascular in vitro responses in human middle meningeal
artery
Middle meningeal artery relaxation to substance P (10
nM) was 51 ± 17% of the precontraction induced by
U46619. As shown in Fig. 1, sumatriptan induced
concentration-dependent contractions that appeared
smaller (albeit non-significant) than those induced by nor-
adrenaline at the highest concentrations (Emax 98 ± 19 vs.
156 ± 22%; P = 0.070; n = 6–7). In contrast, the pEC50
values were significantly higher for sumatriptan than for
noradrenaline (7.0 ± 0.2 vs. 5.8 ± 0.2; P = 0.001; n = 6–7).
Interestingly, isometheptene racemate and its enantio-
mers did not induce any significant contraction, except
when they were administered at the highest concentra-
tion studied (100 μM, a supratherapeutic concentration),
where the enantiomers only induced a modest contrac-
tion (20–40% of 100 mM KCl; P = 0.002; n = 7; Fig. 1).
Vascular responses in human saphenous vein and
coronary artery
In saphenous vein, the endothelium-dependent relax-
ation to 10 μM bradykinin was 19 ± 4% of the precon-
traction induced by U46619. Noradrenaline induced
concentration-dependent contractions, which were lar-
ger and more potent than those induced by sumatriptan
(Emax 111 ± 9 vs. 51 ± 10%; P < 0.001 and pEC50 6.9 ± 0.1
vs. 6.3 ± 0.2; P = 0.019; n = 9–10). Isometheptene racem-
ate, as well as its enantiomers, did not produce venocon-
traction, even at the highest concentrations tested (up to
100 μM). In the proximal and distal coronary segments,
the endothelium-dependent relaxations to substance P
were 31 ± 3 and 83 ± 7% of the precontraction induced
by U46619, respectively. As shown in Fig. 1, the con-
tractile responses to sumatriptan and the corresponding
pEC50 values did not significantly differ between the
proximal and distal segments of the coronary artery
(Emax 19 ± 6 vs. 45 ± 17%; p = 0.15 and pEC50 6.3 ± 0.2 vs.
Fig. 1 Concentration response curves to sumatriptan, noradrenaline, isometheptene enantiomers and isometheptene racemate on the middle meningeal
artery (n= 6–7), saphenous vein (n= 7–10), as well as proximal (n = 7–10) and distal (n= 8–9) coronary arteries
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6.2 ± 0.1; p = 0.65; n = 9–10), respectively. Noradrenaline
was devoid of contractile effects in both artery segments;
the same was true for isometheptene racemate and its
enantiomers.
Effect of isometheptene enantiomers and racemate per se
on MAP and dural artery diameter in vivo
In the closed cranial window experiments, the baseline
value of MAP was 92 ± 5mmHg (n = 12). As shown in
Fig. 2 (left panel), i.v. injection of both isometheptene
enantiomers and the racemate produced significant
vasopressor responses (P < 0.001; n = 12 each). Remark-
ably, (S)-isometheptene produced more pronounced
vasopressor responses than isometheptene racemate and
(R)-isometheptene (39 ± 7, 27 ± 4 and 23 ± 4mmHg, re-
spectively; P = 0.004; n = 12).
In the dural artery, the administration of (S)-iso-
metheptene, (R)-isometheptene or isometheptene racem-
ate produced a significant (P < 0.001, n = 12) small,
short-lasting decrease in dural artery diameter (12 ± 2%,
13 ± 2% and 10 ± 2% of baseline diameter, respectively;
Fig. 2 right panel), which did not differ amongst the ago-
nists (P = 0.34; n = 12). The dural artery diameter and
MAP values restored to pre-injection levels by the time
the next vasodilation was elucidated. At the end of the
experiments, the value of MAP (88 ± 5mmHg) was not
significantly different from the initial baseline value (P =
0.53; n = 12).
Effect of ES, capsaicin or CGRP on MAP and dural
diameter
In none of the experiments ES (150–300 μA) affected
MAP. The i.v. administration of 10 μg/kg capsaicin or
1 μg/kg CGRP produced, as compared to baseline, a simi-
lar decrease in MAP of 19 ± 7 and 24 ± 8mmHg (P = 0.68;
n = 4), respectively. Regarding dural artery diameter, a
similar vasodilation was produced after ES and adminis-
tration of capsaicin or CGRP (62 ± 7, 42 ± 5 and 55 ± 8%
of baseline diameter, respectively; P = 0.29; n = 4 each).
Effect of isometheptene enantiomers and the racemate
on the dural vasodilatory responses
After pretreatment with (S)-isometheptene, (R)-iso-
metheptene or isometheptene racemate, the increases in
dural artery diameter (percent change from baseline)
evoked by ES (49 ± 9, 56 ± 6 and 44 ± 11%, respectively;
P = 0.48), capsaicin (34 ± 5, 28 ± 2 and 26 ± 13%, respect-
ively; P = 0.42), or CGRP (49 ± 9, 56 ± 6 and 44 ± 11%, re-
spectively; P = 0.84) were similar (n = 4 each) to their
respective controls in all groups (Fig. 3).
Discussion
Apart from the implications discussed below, the present
study shows the importance of analysing, in an integra-
tive way, the properties of novel antimigraine drugs
(namely the isometheptene enantiomers) in different ex-
perimental models. Within this context: the use of dif-
ferent human isolated blood vessels allows us to discern
possible vascular side effects induced by potential anti-
migraine agents; and the rat closed-cranial window is an
in vivo neurovascular migraine model that focuses on
the pathophysiological interaction of the trigeminal sys-
tem with neurogenic dural vasodilation [21].
Human vascular (side) effects
A limitation of the current specific antimigraine drugs (i.e.
triptans and ergots) is their theoretical risk of coronary
vasoconstriction, consequently all vasoactive antimigraine
agents are contraindicated in patients with cardiovascular
risk factors or coronary artery disease [22]. With this in
Fig. 2 Effect per se of i.v. bolus injections of (S)-isometheptene, (R)-isometheptene and the racemate (3mg/kg each) on mean arterial pressure (MAP) and
dural artery diameter; all compounds produced significant vasopressor responses and dural vasoconstriction (P< 0.05); * p< 0.05 as compared
to (S)-isometheptene
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mind, we investigate the vasomotor effects of the iso-
metheptene enantiomers in different human blood vessels,
including the proximal and distal coronary arteries; add-
itionally, the human saphenous vein was included as a
positive control of peripheral venoconstriction that is sen-
sitive to α-adrenergic stimulation [23]. Importantly, the
isometheptene enantiomers and the racemate were devoid
of vasoconstrictor properties in the proximal and distal
coronary arteries, as well as the saphenous veins at all
concentrations tested.
Similarly, the isometheptene enantiomers were devoid
of meningeal contractile effects, except when they were
administered at the highest concentration (100 μM,
Fig. 1), a supratherapeutic concentration that would
never be reached in the clinical situation. Regarding the
possible mechanism of action of this meningeal vaso-
constriction, it is tempting to speculate that it is medi-
ated by an indirect (tyramine-like) action, resulting in
noradrenaline displacement from perivascular sympa-
thetic nerve terminals [24], as previously shown for
(R)-isometheptene-induced vasopressor responses [25].
Admittedly, we did not test this hypothesis with experi-
ments in the presence of neuronal reuptake inhibitors
such as cocaine, because, as mentioned before, this
phenomenon only happens at supratherapeutic concen-
trations and is thus unlikely to be clinically relevant.
In contrast to the meningeal artery, there were no
tyramine-like vasoconstrictor effects in coronary arteries,
mainly because these vessels (via β2-adrenoceptors in
vascular smooth muscle) normally dilate to (displaced)
noradrenaline [26], as is evident from the lack of con-
traction after exogenous noradrenaline. Similarly, no
tyramine-like responses were observed in saphenous
veins; this may be attributed to a lesser sympathetic
innervation (vs. arteries) and the possibility that an im-
portant amount of perivascular fibres [present in the
Fig. 3 Effect of i.v. bolus injections of isometheptene enantiomers or the racemate (3mg/kg) on dural vasodilation induced by periarterial electrical
stimulation (150–300 μA, upper panels), capsaicin (10 μg/kg, middle panels) or α-CGRP (1 μg/kg, lower panels) in anesthetized rats (n= 4 in each group);
(S)-IMH, (S)-isometheptene; (R)-IMH, (R)-isometheptene; (RS)-IMH, isometheptene racemate
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loose connective tissue surrounding the vein, [27] were
destroyed.
Thus, on the basis of these results, the well-established
antimigraine action of isometheptene racemate [7, 8, 11],
and probably also of isometheptene enantiomers [in par-
ticular the antimigraine potential of (R)-isometheptene]
would seem to be devoid of acute coronary side effects.
In vivo effects of isometheptene on MAP
In this study, and in accordance with others [25, 28], iso-
metheptene racemate and (S)-isometheptene are potent
vasopressor compounds in rats. Their vascular responses
are mediated by an indirect (tyramine-like action) and a
minor direct stimulation of α1-adrenoceptors [28]. In con-
trast, vascular responses to (R)-isometheptene are exclu-
sively indirect (tyramine-like action) and of less magnitude
than its counterpart enantiomer [25]. Accordingly, (R)-iso-
metheptene might produce fewer vascular side effects as an
antimigraine agent.
In vivo effects of isometheptene on dural artery diameter
In contrast to the lack of vasoconstriction in the isolated
human middle meningeal artery, the isometheptene en-
antiomers and the racemate produced equipotent men-
ingeal vasoconstrictor responses in vivo (Fig. 2). This
apparent in vitro/in vivo discrepancy suggests that iso-
metheptene’s vasoconstriction is indeed mediated by a
tyramine-like action mechanism, which is more evident
when the perivascular sympathetic tone is higher (i.e. in
vivo), whereas such neurogenic tone has been eliminated
in vitro. Although it is believed that the marked dural
vasoconstriction of ergots [17] and triptans [29], along
with the inhibition of intracranial trigeminal afferents
[21] contributes to the peripheral antimigraine mecha-
nisms of these drugs, it is unlikely that isometheptene’s
antimigraine action is related to this small, short-lasting
decrease in dural artery diameter. Therefore, we pro-
ceeded to explore whether the attenuation of
experimentally-activated trigeminovascular afferents
could explain isometheptene antimigraine efficacy.
Modulation of perivascular CGRP release as antimigraine
treatment
The rat closed cranial window method is a highly predictive
model of antimigraine action, in which triptans [21] and
CGRP receptor antagonists [gepants and CGRP (recep-
tor)-binding antibodies [30] have shown its ability to inhibit
neurogenic (CGRP-mediated) vasodilation of the dural
middle meningeal artery as one of their pharmacological
sites of action. It is noteworthy that the isometheptene en-
antiomers and the racemate did not reduce the dural vaso-
dilation evoked by the release of endogenous CGRP (by ES
or i.v. capsaicin) or exogenous CGRP (Fig. 3). Hence, inhib-
ition of trigeminal CGRP release, as one of the mechanisms
associated with antimigraine action (or vasoconstriction),
does not appear to explain isometheptene’s antimigraine ef-
ficacy. Interestingly, it has previously been shown that
imidazoline I1 and α2-adrenoceptor agonists are capable of
inhibiting prejunctionally the sensory vasodepressor
CGRPergic outflow in pithed rats [25, 31]. However,
(R)-isometheptene, an imidazoline I1 receptor agonist with
extremely low affinity for α2-adrenoceptors [12], did not
inhibit the neurogenic dural vasodilation induced by tri-
geminal stimulation; suggesting a differential receptor ex-
pression between sensory and trigeminal afferents, as
previously shown for α2-adrenoceptors [32]. This suggests
that in the rat closed cranial window model, imidazoline I1
and α2 receptors do not play a role as prejunctional modu-
lators of CGRP release in the trigeminovascular system.
Even though similar sample sizes have been used by two
different research groups [32, 33], it could be argued that
the statistical power of our in vivo experiments is low
(and a limitation) due to the relatively small number of
animals used per group. However, when comparing our
current results with those of earlier findings using suma-
triptan [21] and CGRP antagonists [30], the magnitude of
inhibition of CGRP release is remarkably high (up to ca.
70%, and own experiments, data not shown). Thus, while
we cannot categorically exclude that a higher number of
animals could have produced statistically significant ef-
fects, such effects would be rather limited and, probably,
devoid of clinical relevance, as an i.v. dose of 3 mg/kg iso-
metheptene is already supramaximal in pithed rats [25].
Future perspectives for (R)-isometheptene
Isometheptene racemate as monotherapy or, as usual, com-
bined with other drugs (e.g. analgesics), seems a
cost-effective alternative (vs. the triptans) in some countries
for the acute treatment of mild-to-moderate primary head-
aches [8, 10]. Whereas (R)-isometheptene has been shown
not to be effective in the treatment of episodic tension-type
headache (https://news-events/news-events/press-releases/
detail/1004/tonix-pharmaceuticals-reports-top-line-results-
from-phase-2), its antimigraine efficacy has not yet been clin-
ically tested. Overall, after considering the above pharmaco-
logical profile of (R)-isometheptene, it is not unreasonable to
suggest that its potential clinical use as an antimigraine agent
may have superior therapeutic advantages over either iso-
metheptene racemate or (S)-isometheptene. Most import-
antly, the fact that (R)-isometheptene produced only a slight
increase in MAP suggests that it is not directly associated
with the intracranial vasoconstriction previously described
with the racemate [9, 10].
As an imidazoline I1 receptor agonist, (R)-isomethep-
tene should possess central antinociceptive properties, as
previously shown for other imidazolines agonists [34].
This is supported by a preliminary study where high doses
of (R)-isometheptene decreased trigeminal sensitivity in
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two rat models of chronic migraine, and this effect was as-
sociated with a reduced CGRP immunoreactivity in the
trigeminal nucleus caudalis. Certainly, further experi-
ments, falling beyond the scope of the present study, will
be required to investigate whether: (i) (R)-isometheptene
is capable of inducing central antinociception; (ii) activa-
tion of imidazoline receptors translates into acute or
prophylactic antimigraine action; and (iii) selective imida-
zoline I1 receptor agonists can be developed as novel anti-
migraine agents.
Conclusion
It is noteworthy that the isometheptene racemate and its
enantiomers displayed a relatively safe peripheral vascular
profile, as they failed to constrict the human coronary
artery. Isometheptene’s antimigraine action appears unre-
lated to modulation of the trigeminovascular system and
CGRP release, but most likely involves central mechanisms.
The exact site and mechanism for antinociceptive modula-
tion still remains to be elucidated.
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